Palisade Bio (PALI) Competitors $0.69 -0.06 (-8.46%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.01 (+1.42%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. DARE, MBRX, LIXT, ADAP, CMMB, PULM, SYBX, LSB, HOTH, and LPCNShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Dare Bioscience (DARE), Moleculin Biotech (MBRX), Lixte Biotechnology (LIXT), Adaptimmune Therapeutics (ADAP), Chemomab Therapeutics (CMMB), Pulmatrix (PULM), Synlogic (SYBX), LakeShore Biopharma (LSB), Hoth Therapeutics (HOTH), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Dare Bioscience Moleculin Biotech Lixte Biotechnology Adaptimmune Therapeutics Chemomab Therapeutics Pulmatrix Synlogic LakeShore Biopharma Hoth Therapeutics Lipocine Palisade Bio (NASDAQ:PALI) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings. Does the media refer more to PALI or DARE? In the previous week, Dare Bioscience had 13 more articles in the media than Palisade Bio. MarketBeat recorded 16 mentions for Dare Bioscience and 3 mentions for Palisade Bio. Dare Bioscience's average media sentiment score of 0.63 beat Palisade Bio's score of -0.50 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, PALI or DARE? Palisade Bio has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Which has stronger earnings & valuation, PALI or DARE? Dare Bioscience has lower revenue, but higher earnings than Palisade Bio. Dare Bioscience is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K25.18-$14.44M-$4.06-0.17Dare Bioscience-$17.70K-1,584.00-$4.05M-$2.14-0.97 Do institutionals & insiders hold more shares of PALI or DARE? 11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 0.7% of Palisade Bio shares are owned by company insiders. Comparatively, 4.8% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is PALI or DARE more profitable? Dare Bioscience's return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -214.94% -135.09% Dare Bioscience N/A N/A -103.70% Do analysts rate PALI or DARE? Palisade Bio presently has a consensus price target of $12.00, suggesting a potential upside of 1,638.63%. Dare Bioscience has a consensus price target of $12.00, suggesting a potential upside of 476.92%. Given Palisade Bio's higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPalisade Bio and Dare Bioscience tied by winning 7 of the 14 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.30M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-0.1720.9030.1925.84Price / Sales25.18386.36473.64122.75Price / CashN/A43.2325.7828.79Price / Book0.259.649.425.99Net Income-$14.44M-$54.08M$3.27B$265.29M7 Day Performance-13.83%2.62%2.05%2.53%1 Month Performance-40.50%4.05%3.58%0.93%1 Year Performance-79.88%9.48%30.09%18.70% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.7695 of 5 stars$0.69-8.5%$12.00+1,638.6%-78.0%$6.30M$250K-0.1710News CoverageDAREDare Bioscience2.5169 of 5 stars$2.03-3.8%$12.00+491.1%-40.3%$18.33M-$17.70K-0.9530MBRXMoleculin Biotech3.0441 of 5 stars$0.60-1.2%$4.00+566.7%-76.3%$18.17MN/A0.0020LIXTLixte Biotechnology0.0489 of 5 stars$3.90+2.0%N/A+89.4%$17.90MN/A-3.044ADAPAdaptimmune Therapeutics2.039 of 5 stars$0.07-4.1%$1.35+1,914.4%-95.3%$17.79M$65.09M-0.10490Gap DownHigh Trading VolumeCMMBChemomab Therapeutics3.3303 of 5 stars$0.94+0.2%$8.50+802.3%-36.4%$17.77MN/A-1.6020News CoverageAnalyst RevisionPULMPulmatrix0.3994 of 5 stars$4.79+1.6%N/A+144.5%$17.47M$369K-2.2120Positive NewsSYBXSynlogicN/A$1.49+3.8%N/A-2.7%$17.37MN/A-0.5980LSBLakeShore BiopharmaN/A$0.81-0.7%N/A-81.4%$16.87M$85.67M0.00773HOTHHoth Therapeutics2.6001 of 5 stars$1.27-1.6%$4.00+215.0%+71.3%$16.84MN/A-1.194Positive NewsAnalyst DowngradeLPCNLipocine2.4149 of 5 stars$3.07+1.8%$9.00+193.6%-15.3%$16.61M$11.20M-3.5210News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies DARE Alternatives MBRX Alternatives LIXT Alternatives ADAP Alternatives CMMB Alternatives PULM Alternatives SYBX Alternatives LSB Alternatives HOTH Alternatives LPCN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access